| 81.7 0.44 (0.54%) | 04-15 11:40 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 97.83  |
1-year : | 114.26 |
| Resists | First : | 83.76 |
Second : | 97.83 |
| Pivot price | 75.08 |
|||
| Supports | First : | 71.61 |
Second : | 64.09 |
| MAs | MA(5) : | 79.72 |
MA(20) : | 74.69 |
| MA(100) : | 57.79 |
MA(250) : | 42.21 |
|
| MACD | MACD : | 3.3 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 94.4  |
D(3) : | 94.1 |
| RSI | RSI(14): 65 |
|||
| 52-week | High : | 83.76 | Low : | 7.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NKTR ] has closed below upper band by 13.8%. Bollinger Bands are 2.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 81.54 - 81.87 | 81.87 - 82.18 |
| Low: | 77.32 - 77.67 | 77.67 - 78.02 |
| Close: | 80.67 - 81.25 | 81.25 - 81.8 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Wed, 15 Apr 2026
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive - Seeking Alpha
Tue, 14 Apr 2026
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Tue, 14 Apr 2026
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile
Mon, 13 Apr 2026
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 60.9 (%) |
| Shares Short | 3,670 (K) |
| Shares Short P.Month | 3,490 (K) |
| EPS | -9.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.4 |
| Profit Margin | -297.1 % |
| Operating Margin | -87.6 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -218 % |
| Qtrly Rev. Growth | -25.3 % |
| Gross Profit (p.s.) | 1.92 |
| Sales Per Share | 1.92 |
| EBITDA (p.s.) | -4.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -209 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -8.39 |
| PEG Ratio | 0 |
| Price to Book value | 18.5 |
| Price to Sales | 42.38 |
| Price to Cash Flow | -11.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|